The DOI matches its Crossref record.
Phase I/IIa Safety, Immunogenicity, and Efficacy Trial of NYVAC‐Pf7, a Pox‐Vectored, Multiantigen, Multistage Vaccine Candidate for Plasmodium falciparum Malaria
Open accessAbstract
Candidate malaria vaccines have failed to elicit consistently protective immune responses against challenge with Plasmodium falciparum. NYVAC-Pf7, a highly attenuated vaccinia virus with 7 P. falciparum genes inserted into its genome, was tested in a phase I/IIa safety, immunogenicity, and efficacy vaccine trial in human volunteers. Malaria genes inserted into the NYVAC genome encoded proteins from all stages of the parasite's life cycle. Volunteers received three immunizations of two different dosages of NYVAC-Pf7. The vaccine was safe and well tolerated but variably immunogenic. While antibody responses were generally poor, cellular immune responses were detected in >90% of the volunteers. Of the 35 volunteers challenged with the bite of 5 P. falciparum-infected Anopheles mosquitoes, 1 was completely protected, and there was a significant delay in time to parasite patency in the groups of volunteers who received either the low or high dose of vaccine compared with control volunteers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria
Beeson, J. G., Drew, D. R., Boyle, M. J., Feng, G., Fowkes, F. J. I., & Richards, J. S. (2016) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuw001 · Cited by 362
Guerin, P. J., Olliaro, P., Nosten, F., Druilhe, P., Laxminarayan, R., Binka, F., Kilama, W. L., Ford, N., & White, N. J. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00372-9 · Cited by 357
Currier, J. R., Kuta, E. G., Turk, E., Earhart, L. B., Loomis-Price, L., Janetzki, S., Ferrari, G., Birx, D. L., & Cox, J. H. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(01)00535-x · Cited by 320
Progress and challenges for malaria vaccines
Richie, T. L., & Saul, A. (2002) · Nature · doi:10.1038/415694a · Cited by 303
Apical membrane antigen 1: a malaria vaccine candidate in review
Remarque, E. J., Faber, B. W., Kocken, C. H. M., & Thomas, A. W. (2008) · Trends in Parasitology · doi:10.1016/j.pt.2007.12.002 · Cited by 284
Experimental human challenge infections can accelerate clinical malaria vaccine development
Sauerwein, R. W., Roestenberg, M., & Moorthy, V. S. (2011) · Nature Reviews Immunology · doi:10.1038/nri2902 · Cited by 267
Metadata
- Authors
- Ockenhouse, C. F., Sun, P., Lanar, D. E., Wellde, B. T., Hall, B. T., Kester, K., Stoute, J. A., Magill, A., Krzych, U., Farley, L., Wirtz, R. A., Sadoff, J. C., Kaslow, D. C., Kumar, S., Church, L. W. P., Crutcher, J. M., Wizel, B., Hoffman, S., Lalvani, A., Hill, A. V. S., Tine, J. A., Guito, K. P., Taisne, C. D., Anders, R., Horii, T., Paoletti, E., & Ballou, W. R.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-06
- Volume
- 177
- Issue
- 6
- Pages
- 1664-1673
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2148780611
- Cited by
- 226
- References
- 0
- FWCI
- 18.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.